[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"triple-negative-breast-cancer-tnbc-stage-ii-iii\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:triple-negative-breast-cancer-tnbc-stage-ii-iii":26},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,1,0,[8],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":14,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":4,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":28,"lastUpdatePostDateStruct":29,"startDateStruct":32,"completionDateStruct":34,"leadSponsor":36,"locationsCount":5},"100658077","emergence-of-predictive-metabolomic-biomarkers-of-response-to-neoadjuvant-chemoimmunotherapy-in-triple-negative-breast-cancer-100658077",false,"NCT07847398","Emergence of Predictive Metabolomic Biomarkers of Response to Neoadjuvant Chemoimmunotherapy in Triple-Negative Breast Cancer.","EMMENEO-TN","Inclusion Criteria:\n\n* Age 18 years or older.\n* Female patient with stage II and III triple-negative breast cancer, requiring neoadjuvant chemo-immunotherapy according to the KEYNOTE-522 regimen or any neoadjuvant treatment including chemotherapy and immunotherapy validated in standard care or a clinical trial, regardless of the treatment regimen (ER \\\u003C 10%, PR \\\u003C 10%, HER2 0, and HER2 low).\n* Patient requiring the placement of a localization clip as part of their standard clinical care management.\n* Patient who has read the information sheet and signed the informed consent.\n* Patient affiliated with a Social Security health insurance scheme.\n\nExclusion Criteria:\n\n* Metastatic breast cancer documented by staging workup (PET scan or thoraco-abdomino-pelvic CT scan + bone scan).\n* Patient who has undergone primary surgery.\n* INR \\\u003C 1.5; Platelets \\\u003C 50,000\u002F$\\\\mu$L.\n* Patient presenting with multiple primary malignant tumors.\n* Patient with HIV infection, Hepatitis C, or active Hepatitis B.\n* Patient taking:\n* Dual antiplatelet therapy: Acetylsalicylic acid + Clopidogrel without the possibility of suspending Clopidogrel for 5 days,\n* Ticagrelor without the possibility of suspension for 5 days,\n* Prasugrel without the possibility of suspension for 7 days,\n* Vitamin K antagonists (acenocoumarol, warfarin, or fluindione) with INR \\\u003C 2 or \\> 3, without the possibility of suspension.","FEMALE","18 Years",{"count":19,"type":20},50,"ESTIMATED","INTERVENTIONAL",[23],"NA","The goal of this study is to investigate whether specific metabolic profiles can predict response to neoadjuvant chemo-immunotherapy in patients with stage II and III triple-negative breast cancer (TNBC).\n\nThe main objectives are to determine:\n\n* whether targeted metabolic pathways, specifically tryptophan and diacetylspermine metabolism, are associated with histological response to neoadjuvant treatment;\n* whether untargeted metabolomics combined with machine learning approaches can identify novel biomarkers predictive of treatment response.\n\nParticipants will:\n\n* undergo image-guided tumor sampling during the standard-of-care placement of the tumor localization clip, prior to initiation of neoadjuvant chemo-immunotherapy, in accordance with routine clinical practice at the study center;\n* provide a blood sample before initiation of neoadjuvant chemo-immunotherapy;\n* provide a second blood sample during the course of standard treatment; continue to receive routine clinical care, including imaging assessments and surgical management, according to standard clinical practice.\n\nThe study does not modify the patient's standard therapeutic management.",[26],"Triple-negative Breast Cancer (TNBC), Stage II-III","NOT_YET_RECRUITING","2026-09-28",{"date":30,"type":31},"2026-09-29","ACTUAL",{"date":33,"type":20},"2026-10",{"date":35,"type":20},"2029-05",{"name":37,"class":38},"Centre Antoine Lacassagne","OTHER"]